83 results
Page 2 of 5
8-K
EX-99.1
fl0g6netuitg6cknmyt
12 Aug 22
Axcella Reports Second Quarter Financial Results and Provides Business Update
8:11am
8-K
EX-99.1
5vvw8y28 z8nh8j5xny0
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
g063pj
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.2
2w5temtwn2iodwx3
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
8-K
EX-99.1
btj cea31le9
26 May 22
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
8:12am
8-K
EX-99.1
t81obd4hpzg16gf
5 May 22
Axcella Reports First Quarter Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
mrwbua1w
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
8-K
EX-10.1
50u68zpmfx wt8ivi1p
16 Mar 22
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At the Market
8:30am
424B5
vlfhel1ihd8f4
16 Mar 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
tn49u8
7 Feb 22
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
4:00pm
8-K
EX-99.1
3hmk0urigs qys
10 Jan 22
Other Events
8:00am
8-K
EX-99.1
xzjzi4ge
7 Dec 21
Departure of Directors or Certain Officers
6:15am
8-K
EX-99.1
u20e 9kz688xgmkt
10 Nov 21
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
8:08am
8-K
EX-10.1
k2b6ez7 9ob66b
7 Sep 21
Entry into a Material Definitive Agreement
4:16pm